ACC 2018: What are the Takeaways of the ODYSSEY Outcomes Trial?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ACC 2018: What are the Takeaways of the ODYSSEY Outcomes Trial?

By Cleveland Clinic Heart, Vascular and Thoracic Institute

441 views

June 14, 2018

Dr. Steve Nissen, Cleveland Clinic Chairman of Cardiovascular Medicine, discusses the results the ODYSSEY trail ...
read more ↘ looking at the PCSK9 inhibitor alirocumab in patients who had a prior acute coronary syndrome and were on maximum statin therapy. Dr. Nissen provides us insight into the results and take-away message.
↖ read less

0 Comments